ArticleCureus2025
A Pseudo-Right Atrial Mass in Massive Pulmonary Embolism: A Case Report Highlighting Multimodality Imaging and Multidisciplinary Team Review.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transthoracic echocardiography (TTE) is often the first-line imaging modality in cardiac assessment due to its accessibility and rapid acquisition. However, compared with cardiac magnetic resonance (CMR), it offers limited tissue characterisation and may misinterpret anatomical variants as pathology. Consequently, multimodality imaging and multidisciplinary team (MDT) review are frequently required for accurate diagnosis. A 44-year-old man presented with acute dyspnoea following long-haul travel. Computerised tomography pulmonary angiography revealed massive bilateral pulmonary emboli without right ventricular strain, and he was treated with rivaroxaban 20 mg once a day. Three months later, follow-up TTE demonstrated a right atrial mass, reported as a possible thrombus, prompting anticoagulation change to warfarin. At six months, CMR showed no intracardiac mass. However, repeat TTE at one year again suggested a right atrial mass. A review during the cardiac imaging MDT concluded that the apparent "mass" represented epicardial fat entering the imaging plane. Rivaroxaban 20 mg once a day was reinstated for indefinite anticoagulation. This diagnostic pitfall led to an unnecessary switch to warfarin, highlighting how misinterpretation of anatomical variants can significantly alter clinical management. This case underscores the critical role of multimodality imaging and MDT review in the evaluation of intracardiac masses to prevent misdiagnosis and unnecessary treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.